Taspoglutide
| Clinical data | |
|---|---|
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | subcutaneous |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS number | 275371-94-3  |
| ATC code | None |
| UNII | 2PHK27IP3B  |
| Chemical data | |
| Formula | C152H232N40O45 |
| Mol. mass | 3339.75 g/mol |
 (what is this?) (verify) |
|
Taspoglutide is a pharmaceutical drug. It is a glucagon-like peptide-1 analog, under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.[1] [2]
Two phase II trials reported it was effective and well tolerated.[3]
Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009.[4] Preliminary results in early 2010 were favourable.[5] (At least one of the eight planned phase III trials had not started recruiting by end 2009.[6])
As of September 2010, Roche had halted Phase III clinical trials due to a incidences of serious hypersensitivity reactions and gastrointestinal side effects.[7][8]
[edit] Chemistry
Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.
In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.
[edit] See also
- exenatide (Byetta)
- liraglutide (Victoza)
- albiglutide
[edit] References
- ^ "Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials". Business Wire. June 2008. http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_10/ai_n25492242.
- ^ "Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials". June 2008. http://www.bio-medicine.org/medicine-technology-1/Roche-Moves-Investigational-Diabetes-Drug--Taspoglutide--Into-Phase-III-Clinical-Trials-2379-1/.
- ^ Baggio et al. (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide". http://www.medscape.com/viewarticle/578304.
- ^ "Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint In The First Phase III Clinical Trial". October 2009. http://www.medicalnewstoday.com/articles/169171.php.
- ^ "Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy". February 2010. http://www.genengnews.com/news/bnitem.aspx?name=75286047.
- ^ "A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy". http://www.clinicaltrial.gov/ct2/show/NCT01051011.
- ^ "Roche Halts Trials of Taspoglutide". http://www.medpagetoday.com/Endocrinology/Diabetes/22139.
- ^ "Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended". http://www.medicalnewstoday.com/articles/200893.php.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
